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In the last half of the century, advances in the systemic therapy of cancer, including
chemotherapy, hormonal therapy, targeted therapy, and immunotherapy have been
responsible for improvements in cancer related mortality in developed countries even as
the population continues to age. Although such advancements have yet to beneﬁt all cancer
types, systemic therapies have led to an improvement in overall survival in both the adjuvant
and metastatic setting for many cancers.With the pressure to make therapies available as
soon as possible, the side-effects of systemic therapies, in particular long-term side-effects
are not very well characterized and understood. Increasingly, a number of cancer types
are requiring long-term and even lifelong systemic therapy. This is true for both younger
and older patients with cancer and has important implications for each subset. Younger
patients have an overall greater expected life-span, and as a result may suffer a greater
variety of treatment related complications in the long-term, whereas older patients may
develop earlier side-effects as a result of their frailty. Because the incidence of cancer in
the world will increase over the next several decades and there will be more people living
with cancer, it is important to have an understanding of the potential side-effects of new
systemic therapies. As an introductory article, in this review series, we begin by describing
some of the major advances made in systemic cancer therapy along with some of their
known side-effects and we also make an attempt to describe the future of systemic cancer
therapy.
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INTRODUCTION
“Vous n’êtes rien qu’un empoisonneur!”. . .“You are nothing but
someone who poisons people!” were the ﬁrst words a medical
oncologist, who was just beginning his practice, heard from a
very well respected surgical oncologist at Sir Mortimer B. Davis
Jewish General Hospital approximately 30 years ago. Of course,
such statements were not rare then, at a time when medical
oncology was just beginning to be recognized as a medical spe-
cialty. How was anyone to know that medical oncologists, with
all their “toxic poisons” would actually have some success stories
to describe 30 years down the road? Without a doubt, there have
been a number of advances in systemic therapy for a variety of
cancers, both in the adjuvant and metastatic setting, which have
led to an increase in cure rates and overall survival. Such sys-
temic treatments, to contrast with local therapies such as surgery
or radiotherapy, usually fall into the categories of (a) conventional
cytotoxic chemotherapy, (b) hormonal agents or (c) targeted ther-
apy or immunotherapy. Although one cannot deny these systemic
therapies have been at least partially responsible for improved out-
comes, it is also true that their impact has been greatest in a subset
of cancers, and that these same treatments are associated with a
number of important longer term side-effects. In the ﬁrst part
of this review we summarize the advances achieved in the over-
all treatment of selected cancers, and detail some of the known
long-term side-effects related to conventional chemotherapy and
more brieﬂy on those related to hormonal therapy. In the sec-
ond section of this review, we discuss the rapidly expanding
ﬁeld of targeted and immunotherapy for cancer, and discuss the
likely impacts that these new therapeutic agents may have on the
proﬁle of cancer treatment in general, and treatment-related tox-
icities in particular. While it is important to acknowledge that
many of the successes in improving cancer care and overall sur-
vival result from rapid developments in the use of multimodal
treatment regimens, a detailed discussion of the advances in sur-
gical techniques and radiation therapy is beyond the scope of this
article.
CONVENTIONAL CHEMOTHERAPY/CYTOTOXIC AGENTS
With regards to systemic anti-cancer therapy, conventional
chemotherapy agents or cytotoxic agentswere the ﬁrst agents in the
armamentarium for the war on cancer. Ironically, the real thrust to
study these agents occurred after agents such as nitrogen mustard
gas were used in World War I and autopsies on soldiers revealed
lymphoid hypoplasia and myelosuppression (Gilman and Philips,
1946; Chabner and Roberts , 2005). Over the next several decades
numerous cytotoxic agents were discovered. Categories today
include, but are not limited to, alkylating agents (e.g., cyclophos-
phamide, temozolomide, cisplatin, oxaliplatin), anti-metabolites
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(e.g., methotrexate, cytarabine, ﬂuorouracil, capecitabine), anti-
tumor antibiotics (e.g., doxorubicin, epirubicin, bleomycin),
topoisomerase inhibitors (e.g., etoposide, irinotecan) and micro-
tubule stabilizers (e.g., paclitaxel, docetaxel). Typically, these
agents are not tumor speciﬁc and frequently their administra-
tion results in signiﬁcant toxic effects to non-cancerous tissues.
The success of these agents relies largely upon their differential
toxicity for tumor cells which typically have a high mitotic rate
and increased dependence on continuous supply of biomolecules
for growth, compared to normal non-cancerous tissues. Over the
last several decades, administration of these agents was gener-
ally geared at eliminating all cancer cells in the body, often at
the expense of signiﬁcant acute but reversible toxicity in normal
tissues. The ability of normal tissues to repair chemotherapy-
related damage and recover is key to enabling the patient to
tolerate treatment and survive. As demonstrated below, the use
of cytotoxic agents in this type of treatment strategy has been par-
ticularly successful in a variety of cancers in pediatric and adult
patients.
CANCER IN PEDIATRIC AND YOUNG ADULT PATIENTS
Hodgkin lymphoma (HL) serves as an excellent model to high-
light the early successes of chemotherapy, radiation and combined
modality therapy, but is also a sobering reminder of the long-term
toxicities induced by these treatments in cancer survivors. While
HL was universally fatal 30 years ago, it is now curable in 75–
80% of patients with systemic chemotherapy (Viviani et al., 2011)
consisting of doxorubicin (Adriamycin), bleomycin, vinblastine,
and dacarbazine (ABVD). The current approach and challenge in
the management of HL is balancing toxicity with efﬁcacy, rec-
ognizing that 50% of patients with relapsed HL may be cured
with salvage chemotherapy and autologous stem cell transplant
(Schmitz et al., 2002). Although cytotoxic chemotherapy likely
does play a role in long-term toxicities, radiation therapy is also
recognized as being an important contributor. Long-term toxic-
ities associated with HL therapy include secondary solid tumor
malignancies and premature cardiovascular disease which have
been reported as the leading causes of death in HL survivors
(Hodgson et al., 2007; Castellino et al., 2011). Indeed the absolute
risk of secondary cancers including breast, lung, gastrointesti-
nal, and thyroid cancers at 25 years for patients treated with
both chemotherapy and radiation is ∼22% (van Leeuwen et al.,
1995, 2003; Sankila et al., 1996; Aisenberg et al., 1997; Swerd-
low et al., 2000; Dores et al., 2002; Ng et al., 2002; Aleman et al.,
2003; Hodgson et al., 2007). The risk of breast cancer in women
treated before the age of 20 has been reported as high as 40%
at 10 years (Aisenberg et al., 1997) and the risk of developing
secondary myelodysplasia or acute myelogenous leukemia and
anthracycline induced cardiotoxicity is ∼2 and 7% respectively
(Castellino et al., 2011; van der Pal et al., 2012). As a result trials are
ongoing to try and determine the optimal dosing strategies to suc-
cessfully treatHL and limit these long-term side-effects (Castellino
et al., 2011).
Pediatric acute lymphoblastic leukemia (ALL),40 years ago,was
a uniformly fatal disease. Today, 75 to 80% of children are cured
using a course of combination chemotherapy including an induc-
tion, consolidation and maintenance phase along with intrathecal
chemotherapy injections (Pui et al., 2004; Gatta et al., 2005).
Induction chemotherapy generally consists of steroids along
with vincristine and asparaginase. Consolidation therapy follows
induction therapy and can include a combination of cytarabine,
methotrexate, anthracyclines, alkylating agents, and etoposide.
Maintenance therapy can consist of oral 6-mercaptopurine and
weekly methotrexate. As more and more patients survive, how-
ever, the long-term toxicities are becoming increasingly apparent.
As in HL, radiation therapy is believed to play an important role
in the development of long-term toxicities. Some of the long-term
toxicities recognized to date include moderate to severe neuro-
logical or cognitive impairment in 3–15% of patients, a sixfold
increase in risk of stroke, a threefold increase in risk of short
stature, infertility (in post-pubescent males) and secondary malig-
nancies including brain tumors and secondary leukemia (Ise et al.,
1986; Neglia et al., 1991; Relling et al., 1999; von der Weid and
Swiss Pediatric Oncology Group, 2001; Bowers et al., 2006; Chow
et al., 2007 ). In addition cytotoxic chemotherapy treatment is a
recognized cause of “secondary” leukemias, with the risk reaching
5% for most ALL survivors and a 20% risk in survivors of T cell
ALL at 6 years (Pui et al., 1989).
Pediatric medulloblastoma is the most common malignant
brain tumor of childhood. Over the last 30 years, a multimodality
approach including surgery, chemoradiation, and combination
chemotherapy has improved overall survival to approximately
80% at 5 years (Packer et al., 2006). Chemotherapy agents used
include vincristine, cisplatin with cyclophosphamide or car-
mustine. Chemotherapy administration has been found to be
particularly useful in certain high risk subsets and has also resulted
in the use of less radiation therapy in lower risk groups, reduc-
ing radiation induced toxicity (Rutkowski et al., 2005). Long-term
side-effect studies are few, but there are reports of neurocognitive
impairment, secondary central nervous system tumors, hear-
ing loss, and endocrine abnormalities (Devarahally et al., 2003;
Fouladi et al., 2005, 2008; Laughton et al., 2008).
Ewing’s sarcoma and osteosarcoma, tumors diagnosed pre-
dominantly in the pediatric and young adult populations, have
also seen their prognosis improve signiﬁcantly with the use of
chemotherapy. In both localized Ewing’s sarcoma and osteosar-
coma, neoadjuvant followed by local therapy and subsequent
adjuvant chemotherapy (when indicated) has improved overall
survival from approximately 20% using local control measures
alone to approximately 65–70% at 5 years (Nesbit et al., 1990;
Anninga et al., 2011). Five year survival rates of 20–40% can also
be achieved in patients with isolated lung metastasis with the
appropriate use of multimodality therapy including chemother-
apy (Bacci et al., 1995, 2008). However many of these patients
suffer long-term complications and up to 25% mortality at 25
years (Ginsberg et al., 2010). Causes of death include not only
relapse of disease but also secondary neoplasms, cardiomyopathy,
and pulmonary complications.
Testicular cancer, in large part thanks to a cisplatin-based
chemotherapy regimen, is considered to be the most frequently
cured solid tumor. Even patients with advanced disease including
brainmetastasis have a good chance at cure. Recent reports suggest
that over 95% of males diagnosed with the disease are cured after
10 years of follow-up (Siegel et al., 2011). In general, bleomycin,
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etoposide, and cisplatin (BEP) chemotherapy, remain the standard
of care for the disease in particular for patients with advanced dis-
ease. However, 20–40% of long-term survivors can suffer some
form of otoxicity, neuropathy, and nephropathy (Bokemeyer et al.,
1998; Fossa et al., 2002; Brydoy et al., 2009). Bleomycin lung injury
can also be quite severe and up to 40% of patients will have some
form of toxicity in the ﬁrst 3 years post-chemotherapy. Most of
the cases are mild but up to 10% of cases can develop pulmonary
ﬁbrosis and up to 10% of those can eventually die of their lung
disease (O’Sullivan et al., 2003).
CANCER IN ADULT PATIENTS
Tumors such as colon and breast cancer have also seen an
improvement in survival resulting from the use of conventional
chemotherapy in both the adjuvant and metastatic setting. Stage
III colon cancer patients treated with 6 months of 5-ﬂuorouracil
(5-FU)-based chemotherapy in combination with oxaliplatin have
improved5-year disease free survival rates by 20–30%(Andre et al.,
2004, 2009). In the metastatic setting, with isolated liver or pul-
monary metastasis, 5 year overall survival rates in the 20–40%
range have been reported with multimodality therapy includ-
ing chemotherapy (Adam et al., 2009; Masi et al., 2009). Median
overall survival in the non-operable metastatic colon cancer has
also improved, and now stands at approximately 2 years with the
use of 5-FU-based chemotherapy with oxaliplatin and irinotecan.
In adjuvant breast cancer, combination chemotherapy frequently
containing an anthracycline with a taxane has improved 5 year dis-
ease free survival rates by up to 20%(Berry et al., 2006)depending
on the initial stage of disease and tumor characteristics. Simi-
larly, a wide number of chemotherapy agents are known to be
effective in treating breast cancer and their use, has improved
overall survival in the metastatic setting. Unfortunately, despite
huge improvements in the control of acute chemotherapy-related
symptoms such as chemotherapy-induced nausea and vomiting,
other more insidious or persistent symptoms such as fatigue and
neuropathy have proven more challenging to address. Thus ben-
eﬁts in overall survival in colon cancer due to use of agents such
as oxaliplatin, have to be weighed against the impact of persis-
tent peripheral neuropathy which can affect up to 10% of patients
4 years post-treatment with 1% having severe symptoms (Andre
et al., 2009). Similarly adjuvant chemotherapy in breast cancer
survivors is associated with fatigue, neuropathy, cardiomyopathy,
ovarian dysfunction, leukemia, and psychological distress (Postma
et al., 1995; Partridge and Ruddy, 2007; Beadle et al., 2009; Bowles
et al., 2012).
HORMONAL THERAPY
Hormonal therapy has also played an important role in the
treatment of breast and prostate cancer. Hormonal therapy in
breast cancer has improved disease free survival in ER/PR+
disease by up to 10% at 10 years (Dowsett et al., 2010; Early
Breast Cancer Trialists’ Collaborative Group et al., 2011). In the
metastatic setting, use of hormonal therapy (when appropriate
and often combined with chemotherapy) has likely improved
median overall survival to approximately 2 years with reports of
long-term survivors of 8 years and longer (Gennari et al., 2005;
Chia et al., 2007). Adjuvant hormonal therapy, depending on
whether tamoxifen or an aromatase inhibitor (AIs) is used tends
to be associated with musculoskeletal discomfort, early osteo-
porosis and increased cardiac events for AIs versus increased
venous thromboembolic events and uterine hyperplasia (rarely
malignancy) with tamoxifen (Mincey et al., 2006; Cuppone et al.,
2008; Schaapveld et al., 2008; Amir et al., 2011). With regards to
prostate cancer, in both the adjuvant setting for locally advanced
disease and in overt metastatic disease, androgen deprivation
therapy is associated with an improvement in overall survival
(Nguyen et al., 2011; Hussain et al., 2012). Side-effects from
androgen deprivation therapy include sexual dysfunction, hot
ﬂashes, early osteoporosis complicated by bone fractures and
loss of lean body mass (Shahinian et al., 2005; Wilke et al., 2006;
Smith et al., 2012).
THE FUTURE OF CONVENTIONAL CHEMOTHERAPY
The examples described above demonstrate that conventional
cytotoxic chemotherapy has an important role in the management
of patients diagnosed with cancer, but the use of these agents is
clearly associated with long-term toxicities in long-term survivors.
Moreover we can anticipate that further improvements in cancer
survival related to the increasing use of cytotoxic chemotherapies
in more potent and effective regimens, will also lead to increasing
numbers of patients being affected by the cancer treatment-related
long-term toxicities. Present and future challenges include iden-
tifying the appropriate dosing of cytotoxic agents (and other
components of multimodal anti-cancer treatment regimens) to
maximize therapeutic efﬁcacy while limiting both acute and long-
term side-effects. Individualized assessments of a patients’ risk
of cancer-related death/recurrence is another important conceptual
approach that is being usedmore andmore to adapt the aggressive-
ness of the treatment strategy thus attempting to balance the need
for cancer treatment and the likelihood of treatment-related long-
term toxicities. Indeed a number of trials are ongoing to answer
these questions but these are statistically complex trials that require
a large number of subjects as well as extended follow up (several
years) to accurately capture long-term toxicities. An important
group of patients which require special consideration is the rapidly
expanding population with metastatic incurable disease, where
chemotherapy treatment is frequently used to control cancer
indeﬁnitely. The sequential use of several different chemother-
apy agents is becoming increasingly common to overcome tumor
resistance as it emerges e.g., in patients with metastatic colon and
breast cancer, and there is evidence for improved overall survival.
Nevertheless these patients often accumulate considerable expo-
sure to multiple chemotherapeutic agents, and are thus at high risk
of cumulative treatment-related side-effects. Paradoxically patient
ability or willingness to tolerate such side-effects, rather than
uncontrolled disease, or absence of potential active anti-cancer
treatments, may rapidly become the limiting factor for treatment
success in this population.
TARGETED THERAPY AND IMMUNOTHERAPY
Although the use of cytotoxic chemotherapy has had some notable
success as described above, a signiﬁcant proportion of patients
suffering from cancer either do not respond to conventional
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chemotherapy or relapse after treatment. In addition, several can-
cer types, such as melanoma, renal cell carcinoma, hepatocellular
carcinoma, and gastrointestinal stromal tumors (GIST) have very
limited response to conventional cytotoxic chemotherapy. For
these cancers, patients have frequently received treatments with
minimal beneﬁt but signiﬁcant toxicity, in the hope that this would
slow disease progression in some cases. More recently the ability
to characterize speciﬁc gene mutations in different cancers, and a
greater biological understanding of the cellular events and path-
ways driving carcinogenesis, has led to the development of targeted
agents and immunotherapeutics. These new therapies appear to
offer considerable advantages in delivering growth inhibitory or
cytotoxic effects in a much more cell-speciﬁc manner. Further-
more these drugs do not induce the same proﬁle of acute toxicities
such as myelosuppression and nausea and vomiting which accom-
pany many of the conventional non-targeted cytotoxic drugs. As
described below some of the newer targeted agents have proven
highly effective anti-cancer treatments, and have already delivered
startling improvements in survival for certain cancers. However,
many of the cellular pathways which are disrupted in cancer cells
and targeted by these newer treatments, are also of fundamental
importance to normal growth or homeostasis in all cells. Fur-
thermore typical treatments are prolonged, extending over many
months or years. Both these factors suggest there is a reasonable
chance that the targeted agents still carry a risk of effects in other
non-cancer cells. In many cases there is still not enough clinical
experience with these drugs to establish precise or robust long-
term toxicity proﬁles, but as detailed below, many of these agents
do have unforeseen shorter term side-effects and induce variable
degrees of morbidity as a result.
IMATINIB AND THE TREATMENT OF CHRONIC MYELOGENOUS
LEUKEMIA
The impact of Imatinib on outcomes in chronic myelogenous
leukemia (CML) is perhaps the best example of the marked
improvements that targeted treatments have made in cancer treat-
ment. A gene translocation event involving the gene for BCR-ABL
creating a constitutively active tyrosine kinase is a central event in
the genesis of CML. Imatinib, one of a family of tyrosine kinase
inhibitor (TKI) molecules has proven highly effective in the treat-
ment of CML and has had a dramatic impact on the course of this
disease. Prior to imatinib, the majority of patients diagnosed with
CML in the chronic phase would generally progress to a blastic
phase within 5 years of diagnosis and most would die. Since the
introduction of imatinib, the 8 year follow-up of the IRIS study
has described progression free and overall survival of greater than
80% in patients treated with imatinib during chronic phase CML
(Deininger et al., 2009). It is now estimated that the majority of
patients with CML have a normal life expectancy (Gambacorti-
Passerini et al., 2011). For the most part, however, these patients
are not considered cured, rather imatinib maintains a very low
level of CML cells and lifelong therapy may be required. Many
consider imatinib to be the most successful of all the targeted
therapies discovered to date against cancer. This success largely
relates to the relatively simple molecular biology of CML, which
unlike most other cancers, is associated with one dominant single
gene rearrangement resulting in its neoplastic potential.
Imatinib has also been found to be quite active in treat-
ing GIST both in the adjuvant and locally advanced as well
as metastatic setting (Blanke et al., 2008; Joensuu et al., 2012).
GIST frequently overexpresses c-kit and imatinib cross-reacts
and signiﬁcantly inhibits this tyrosine kinase receptor, and as a
result relapse-free survival and progression-free survival have sig-
niﬁcantly improved in this previously chemotherapy-refractory
disease. In advanced disease or metastatic disease, complete
responses are rare but long-term stable disease on imatinib,
can be maintained for 2–3 years. In the adjuvant setting, it is
presently not clear how long patients should remain on ima-
tinib post-resection and some data suggests the longer the better
(Joensuu et al., 2012).
Interestingly, even with the relative selectivity of imatinib,
patients still suffer from a number of side-effects that are likely
from cross-reactivity of the agent with other tyrosine kinases on
healthy tissues. The side-effects of imatinib are generally consid-
ered mild but may persist for as long as the patient remains on
therapy and have been associated with a diminished quality of life
(Efﬁcace et al., 2011). Side-effects include but are not limited to
fatigue, diarrhea, nausea and vomiting along with muscle cramps,
musculoskeletal pains, rash and edema. Other toxicities include
cytopenias, hepatotoxicity, and cardiac toxicity. Long-term toxic-
ities of imatinib and the long-term consequences of the chronic
side-effects described above are not yet known but it should be
noted that after 8 years of follow-up in patients being treated for
CML, no increased risk of secondary cancers has been described
(Verma et al., 2011).
THE ROLE OF TKIs IN NON-SMALL CELL LUNG CANCER
In the last decade, a number of other TKIs have been developed
and have shown some success in treating lung cancers. Erlotinib
and geﬁtinib are TKIs that target a mutated active epidermal
growth factor receptor that is implicated in approximately. 10-
15% of advanced non-small cell lung cancer (NSCLC) tumors.
First-line treatment with either geﬁtinib or erlotinib, in patients
harboring an EGFR mutation with stage IV disease is associated
with an approximately 5–6 month improvement in progression-
free survival when compared to conventional chemotherapy (Mok
et al., 2009; Fukuoka et al., 2011; Zhou et al., 2011; Rosell et al.,
2012). Beneﬁt in overall survival has been difﬁcult to demon-
strate given many trials allowed cross-over and the majority of
patients went on to get 2nd line therapy. Toxicities reported
to date include fatigue, diarrhea, and rash along with hepatic
toxicity and rare events of hepatic failure and interstitial pneu-
monitis. (Liu et al., 2007; Pellegrinotti et al., 2009). Crizotinib,
is another TKI approved in NSCLC after studies have shown
marked and durable responses in patients harboring an anaplas-
tic lymphoma kinase (ALK) fusion oncogene (Kwak et al., 2010).
The ALK fusion oncogene is thought to be present in approx-
imately 2–7% of patients with NSCLC but as is the case for
EGFR mutations,. ALK is predominantly present in young non-
smoking patients. Similar to other TKIs, side-effects associated
with crizotinib include fatigue, diarrhea, nausea, and vomiting
which are rarely severe but there are reports of life-threatening
hepatotoxicity and interstitial pneumonitis (Ouet al.,2011;Weick-
hardt et al., 2012). As with geﬁtinib and erlotinib, data regarding
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crizotinib associated long-term side-effects is very limited given
the short period of time they have actually been approved for
treatment.
TARGETED ANTI-CANCER TREATMENTS FOR RENAL CELL CARCINOMA
With limited efﬁcacy of conventional chemotherapy, targeted ther-
apy has been the predominant focus in renal cell cancers (RCCs)
in particular for clear cell renal cancers. Two classes of agents,
TKIs (predominantly inhibiting vascular endothelial growth
factor tyrosine kinases, vascular endothelial growth factor recep-
tor (VEGFR), but most are multi-targeted TKI) and mammalian
target of rapamycin (mTOR) inhibitors are the key players.
VEGFR-associated pathways have also been shown to have
an important role in clear cell RCC and other cancers, and
VEGFR inhibitors have essentially become the 1st line therapy
in metastatic RCC for most patients. Sunitinib, pazopanib, axi-
tinib, and sorafenib are VEGFR inhibitors that have demonstrated
therapeutic efﬁcacy in metastatic clear cell RCC (Escudier et al.,
2009; Motzer et al., 2009; Sternberg et al., 2010; Rini et al.,
2011). The mTOR inhibitors, temsirolimus, and everolimus, have
also shown activity in metastatic clear cell RCC (Hudes et al.,
2007; Motzer et al., 2008, 2010). Most patients with metastatic
RCC will be started on one of these classes of agents often
resulting in either stability of disease or some degree of partial
response. In almost all cases resistance eventually develops, gener-
ally within 8 months, and 2nd line therapy with a different agent
either in the same class or different class (i.e., VEGFR inhibitors or
mTOR inhibitors) is started. The majority of patients inevitably
remain on such therapies lifelong. The VEGFR inhibitors tend to
have a number of associated toxicities but to date those reported
are mostly for sunitinib and sorafenib simply because the other
agents have less available data. Side-effects include hyperten-
sion, an increase in arterial thromboembolic events, thyroid
dysfunction, cutaneous toxicity, cardiotoxicity, hepatotoxicity,
and skeletal muscle wasting (Motzer et al., 2007; Rini et al.,
2007; Lacouture et al., 2008; Zhu et al., 2009; Choueiri et al.,
2010). Although controversial, pre-clinical studies in mice have
raised concerns that, sunitinib, a multi-targeted TKI which
inhibits VEGF signalling may lead to paradoxical enhancement of
tumor metastatic growth in some tumor models (Iacovelli et al.,
2012). It should be stressed, however, that this potential drawback
of sunitinib has not been demonstrated in humans. Temsirolimus
is associated with rash, nausea, vomiting, and anorexia in 30–
50% of patients but severity is considered mild in most patients
(Hudes et al., 2007). Everolimus can result in severe lymphope-
nia, hyperglycemia, and stomatitis (Motzer et al., 2008, 2010).
Interstitial pneumonitis is reported to occur anywhere between
0.5 and 10% of patients with both everolimus and temsirolimus
(Iacovelli et al., 2012). For both classes, a description of long-
term side-effects is limited by their short duration of time
in use.
THE USE OF MONOCLONAL ANTIBODIES FOR ANTI-CANCER
TREATMENTS
Targeted therapy agents also include a number of monoclonal
antibodies. Examples include trastuzumab, bevacizumab, pani-
tumumab, and cetuximab. In the adjuvant setting trastuzumab,
a monoclonal antibody against Her2 (an EGFR receptor overex-
pressed in approximately 20% of breast cancers), has improved
the overall survival in women with breast cancers overexpress-
ing Her2, by 5–10% at 5 years (Slamon et al., 2011). It has
also been shown to improve overall survival in women suffer-
ing from metastatic disease (Slamon et al., 2001; Marty et al.,
2005). In terms of side-effects, heart failure appears to be the
only major concern and occurs in less than 5% of patients but
generally is reversible if caught early and treatment discontinued
(Perez et al., 2008).
As mentioned previously, the VEGFR pathway is believed to
play an important role in a variety of cancers. Bevacizumab is a
monoclonal antibody against the ligand of VEGFR, and its use has
been shown to increase overall survival by approximately 4months
inmetastatic colon cancer when used in combinationwith irinote-
can (Hurwitz et al., 2004). However, a notable increase in grade
three and four adverse reactions associatedwith bevacizumabwere
also seen which include hypertension, bowel perforation, arterial
thromboembolic events, impaired wound healing, and bleeding
events (Kozloff et al., 2009). Addition of bevacizumab to 5-FU-
based chemotherapy in the adjuvant setting has not shown any
beneﬁt.
Panitumumab and cetuximab are anti-EGFR antibodies that
have been shown to increase overall survival in metastatic colon
cancer by approximately 5 months in chemotherapy refrac-
tory metastatic colon cancer (Van Cutsem et al., 2007, 2008;
Karapetis et al., 2008). These antibodies target the EGFR recep-
tor, K-ras, and beneﬁt patients that have a wild-type K-ras
gene which is found in approximately 40% of patients with
colon cancer. Adverse reactions from these antibodies include
injection reactions, rash, diarrhea, venous thromboembolic
events, and electrolyte abnormalities. Similarly to bevacizumab,
addition of either antibody in addition to standard combina-
tion chemotherapy has not shown any beneﬁt in the adjuvant
setting.
TARGETED ANTI-CANCER TREATMENTS AND IMMUNOTHERAPY FOR
MALIGNANT MELANOMA
For the last 30 years ormore attempts to use conventional cytotoxic
chemotherapy in the treatment of malignantmelanoma resulted in
minimal beneﬁt. Two recent major advances in melanoma include
the development of a family of TKIs termed Braf inhibitors, and
a breakthrough immunotherapeutic agent referred to as ipili-
mumab. Both have demonstrated signiﬁcant beneﬁt in overall
survival in patients with metastatic melanoma (Hodi et al., 2010;
Chapman et al., 2011; Robert et al., 2011). Studies in the adju-
vant setting, however, are ongoing. Braf inhibitors target mutated
Braf tyrosine kinase receptors. Approximately 50% of patients
with cutaneous melanoma have activating Braf mutations. Use
of Braf inhibitors in patient’s harboring the mutated oncogene
results in dramatic disease regressions in >95% of patients.
Unfortunately, resistance eventually develops in between 6 and
12 months for the majority of patients. Ipilimumab is an anti-
CTLA-4 antibody that results in the stimulation of an immune
response against melanoma. Approximately 20–30% of patients
have some degree of response with approximately 10% having
durable remissions for several years. Side-effects of Braf inhibitors
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include arthralgia, fatigue, rash and an increase in the
number of squamous cell carcinomas and keratoacanthomas.
Side-effects from ipilimumab are predominantly related to an
inﬂammatory type autoimmune response on normal body
tissues and include enterocolitis, hepatitis, dermatitis, and
endocrinopathies.
THE FUTURE OF TARGETED AND IMMUNOTHERAPY
Targeted therapy is heralded by many as the holy grail of cancer
treatment, the best example of which is imatinib in the treatment
of CML. In some instances, however, targeted therapies have fallen
short of expectations. Despite showing an improvement in pro-
gression free and overall survival, resistance to these agents can
develop sometimes within a short time of initiation of therapy.
The limited efﬁcacy of these agents in some circumstances likely
reﬂects less on the lack of sophistication of the targeted agents
and more on the genetic instability of tumors and the presence
of tumor subclones which develop resistance or are inherently
resistant to these therapies. Further genetic characterization of
tumors may help to ensure that the right therapy is used in the
right patient. Additionally, a number of these targeted therapies
have important side-effect proﬁles, some being associated with
pulmonary ﬁbrosis, gastrointestinal toxicity, hepatotoxicity, car-
diomyopathy, and other cardiovascular complications. Whilst
these may well be tolerable or acceptable in the short term, where
patients are required to remain on such therapies lifelong the
impact on function and quality of life may be more difﬁcult to
sustain. Despite the many promising and exciting advances in this
area of cancer therapeutics there are alsomany areas of uncertainty
including whether the efﬁcacy demonstrated by imatinib in CML
can ever be replicated with other agents in other cancer types; and
what the long-term health consequences of remaining on these
types of therapies will be. Meanwhile, though optimum treatment
regimens and dosing schedules using targeted therapies are still
to be established, lifelong treatment for many patients seems to
be a likely outcome. Hence the development of new and highly
effective targeted anti-cancer therapies, also brings with it new
challenges: namely how to mitigate not only short-term transient
toxicities, but also the persistent or late side-effects which emerge
when patients have to remain on these therapies for extended peri-
ods. Addressing these challenges will be vital to the continued
success of this collective war on cancer.
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